A Phase I/II to Assess Safety, Tolerability and Efficacy of DL-lactic Acid Syrup in Children With Recurrent Tonsillitis
Phase 1
Completed
- Conditions
- Recurrent Tonsillitis in Children
- Interventions
- Dietary Supplement: Raspberry flavored syrupDrug: DL - Lactic Acid
- Registration Number
- NCT01988558
- Lead Sponsor
- Yali Pharmaceuticals
- Brief Summary
The study objectives are to evaluate Tonsitin™ (10% Lactic Acid) safety, tolerability and preliminary efficacy, as a potent treatment for Recurrent Tonsillitis in children.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 51
Inclusion Criteria
- Children at the ages of 5-16.
- Patient is suffering from recurrent documented sore throat with at least 4 tonsillitis episodes during the preceding year (at least one verified by culture or rapid antigen testing for Streptococcus A).
- Patient with clinical presentation of irregular tonsils.
- Tonsils size graded between 2.5-4.
- Clinical diagnosis of bacterial known in recurrent pharyngeal-tonsillitis.
- Patient is willing to participate in the study and adhere to the study protocol
- Patient's guardian and/or Patient have signed informed consent.
Exclusion Criteria
- Clinical diagnosis of acute tonsillitis/pharyngitis caused by Streptococcus pyogenes (Positive RSAT or microbial culture).
- Subjects who are known as Streptococcus pyogenes carriers
- Subject's requiring any other medication (topical or systemic) that may affect the course of the disease during the study period (e.g. antibiotics, sedating antihistamines), and/or did not completed 14 days from end of antibiotics treatment.
- Subjects with known hypersensitivity to lactose.
- Subject is suffering from peritonsillar abscess.
- Subject suffers from an active peptic ulcer
- Subjects who are suffering from any concomitant disease which in the judgment of the investigator will interfere with the conduct or interpretation of the study results.
- Subject is currently participating in another clinical study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Group Raspberry flavored syrup - Treated Group DL - Lactic Acid Children diagnosed as suffering from recurrent Tonsillitis (at least 4 episodes per year) to receive DL-Lactic acid syrup twice a day for a month.
- Primary Outcome Measures
Name Time Method Safety evaluation - Number of participants with adverse events At 90 days post treatment
- Secondary Outcome Measures
Name Time Method Tonsil Size Chnge from baseline at 6 months post treatment Number of Tonsillitis episodes Chnge in medical history number of recurrent Tonsillitis episodes within 6 months post treatment
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which DL-lactic acid syrup (Tonsitin) modulates immune response in recurrent tonsillitis?
How does Tonsitin's efficacy in treating recurrent tonsillitis compare to antibiotic therapies in pediatric populations?
Are there specific biomarkers that correlate with improved outcomes in children receiving DL-lactic acid syrup for tonsillitis?
What adverse event profiles have been observed in phase I/II trials of lactic acid-based immunomodulators for pediatric infections?
What combination therapies involving lactic acid or other immunomodulatory compounds show promise in managing recurrent tonsillitis?
Trial Locations
- Locations (3)
Clalit Health Services, Pediatric Community Ambulatory Clinic
🇮🇱Petach Tikva, Israel
Clalit Health Services, Pediatric Community Ambulatory Ganei Hadar clinic
🇮🇱Petach Tikva, Israel
Assaf Harofeh Medical Center
🇮🇱Tzrifin, Israel
Clalit Health Services, Pediatric Community Ambulatory Clinic🇮🇱Petach Tikva, Israel